share_log

A Closer Look at 7 Analyst Recommendations For NovoCure

A Closer Look at 7 Analyst Recommendations For NovoCure

深入了解對 NovoCure 的 7 個分析師建議
Benzinga ·  06/04 09:01
7 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives.
最近三個月,有7位分析師對NovoCure(納斯達克股票代碼:NVCR)進行了評估,表達了看好和看淡的觀點。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級,展示了過去30天內不斷變化的情緒,並將其與前幾個月進行了比較。
Analysts have recently evaluated NovoCure and provided 12-month price targets. The average target is $25.29, accompanied by a high estimate of $42.00 and a low estimate of $17.00. This current average has decreased by 3.36% from the previous average price target of $26.17.
分析師最近對NovoCure進行了評估,並提供了爲期12個月的目標股價。平均目標價格爲25.29美元,高估值爲42.00美元,低估值爲17.00美元。這個當前的平均目標價格比之前的26.17美元的平均目標價格下降了3.36%。
Deciphering Analyst Ratings: An In-Depth Analysis
分析師評級解讀:深入分析
A comprehensive examination of how financial experts perceive NovoCure is derived...
對綜合了近期分析師行動...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論